Emerging evidence highlights a potential role for ACE in treating Alzheimer’s disease (AD) due to its capacity to degrade amyloid beta 1–42 (Aβ1–42). The gene discussed is ACE; the disease is early-onset autosomal dominant Alzheimer disease.